Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 99


Phosphorylation of the PTEN tail regulates protein stability and function.

Vazquez F, Ramaswamy S, Nakamura N, Sellers WR.

Mol Cell Biol. 2000 Jul;20(14):5010-8.


Stabilization and productive positioning roles of the C2 domain of PTEN tumor suppressor.

Georgescu MM, Kirsch KH, Kaloudis P, Yang H, Pavletich NP, Hanafusa H.

Cancer Res. 2000 Dec 15;60(24):7033-8.


The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.

Georgescu MM, Kirsch KH, Akagi T, Shishido T, Hanafusa H.

Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10182-7.


Membrane-binding and activation mechanism of PTEN.

Das S, Dixon JE, Cho W.

Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7491-6. Epub 2003 Jun 13.


Regulation of cell migration by the C2 domain of the tumor suppressor PTEN.

Raftopoulou M, Etienne-Manneville S, Self A, Nicholls S, Hall A.

Science. 2004 Feb 20;303(5661):1179-81.


Targeting mutants of PTEN reveal distinct subsets of tumour suppressor functions.

Leslie NR, Bennett D, Gray A, Pass I, Hoang-Xuan K, Downes CP.

Biochem J. 2001 Jul 15;357(Pt 2):427-35.


Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity.

Koul D, Jasser SA, Lu Y, Davies MA, Shen R, Shi Y, Mills GB, Yung WK.

Oncogene. 2002 Apr 4;21(15):2357-64.


PTEN blocks insulin-mediated ETS-2 phosphorylation through MAP kinase, independently of the phosphoinositide 3-kinase pathway.

Weng LP, Brown JL, Baker KM, Ostrowski MC, Eng C.

Hum Mol Genet. 2002 Jul 15;11(15):1687-96. Erratum in: Hum Mol Genet. 2003 Aug 1;12(15):1943.


The tumour-suppressor function of PTEN requires an N-terminal lipid-binding motif.

Walker SM, Leslie NR, Perera NM, Batty IH, Downes CP.

Biochem J. 2004 Apr 15;379(Pt 2):301-7.


PTEN 2, a Golgi-associated testis-specific homologue of the PTEN tumor suppressor lipid phosphatase.

Wu Y, Dowbenko D, Pisabarro MT, Dillard-Telm L, Koeppen H, Lasky LA.

J Biol Chem. 2001 Jun 15;276(24):21745-53. Epub 2001 Mar 2.


FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer.

Modur V, Nagarajan R, Evers BM, Milbrandt J.

J Biol Chem. 2002 Dec 6;277(49):47928-37. Epub 2002 Sep 25.


Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex.

Vazquez F, Grossman SR, Takahashi Y, Rokas MV, Nakamura N, Sellers WR.

J Biol Chem. 2001 Dec 28;276(52):48627-30. Epub 2001 Nov 13.


Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay.

Han SY, Kato H, Kato S, Suzuki T, Shibata H, Ishii S, Shiiba K, Matsuno S, Kanamaru R, Ishioka C.

Cancer Res. 2000 Jun 15;60(12):3147-51.


Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association.

Lee JO, Yang H, Georgescu MM, Di Cristofano A, Maehama T, Shi Y, Dixon JE, Pandolfi P, Pavletich NP.

Cell. 1999 Oct 29;99(3):323-34.


PTEN expression elicited by EGR-1 transcription factor in calyculin A-induced apoptotic cells.

Okamura H, Yoshida K, Morimoto H, Haneji T.

J Cell Biochem. 2005 Jan 1;94(1):117-25.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk